Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides

Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides

10.18632/oncotarget.20658

Saved in:

Bibliographic Details
Main Authors:	Liu, J, Bhadra, M, Sinnakannu, J.R, Yue, W.L, Tan, C.W, Rigo, F, Ong, S.T, Roca, X
Other Authors:	DUKE-NUS MEDICAL SCHOOL
Format:	Article
Published:	2020
Subjects:	antisense oligonucleotide BH3 protein BIM protein cis acting element imatinib protein tyrosine kinase inhibitor RNA isoform serine arginine rich splicing factor alternative RNA splicing apoptosis Article BIM gene cancer adjuvant therapy cancer resistance chronic myeloid leukemia chronic myeloid leukemia cell line controlled study DNA sequence drug mechanism enzyme inhibition exon gene deletion gene switching genetic association genetic code human human cell K-562 cell line KCL-22 cell line protein domain RNA splicing
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/179546
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

Description
Summary:	10.18632/oncotarget.20658